clinical trial · NCT07073690
Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China
Bristol-Myers Squibb·—·completed·n = 88
Myelodysplastic SyndromesLuspatercept
brief summary
The purpose of this study is to evaluate the treatment patterns and clinical outcomes in adults with lower-risk MDS (LR-MDS) who were erythropoiesis-stimulating agents (ESA)-naïve and received luspatercept treatment in China
started
Apr 18, 2025
primary completion
May 12, 2026
completion
May 12, 2026
last updated
May 19, 2026
official title
Real-World Treatment Patterns and Outcomes of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes (LR-MDS) in China ('REACH' Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol